What is the annual cost of dupilumab for COPD?
Dupilumab (Dupixent) is approved for several inflammatory conditions, but it is not approved for COPD. Because there is no established, labeled COPD regimen for dupilumab, an “annual cost of dupilumab for COPD” depends on whether you mean off-label use (which varies widely by dose, payer, and country) or an approved COPD biologic/other therapy instead.
What cost information is available if dupilumab is used off-label for COPD?
The annual cost is not a single fixed number for COPD because:
- Off-label prescribing can differ in dose and treatment duration.
- Insurance coverage for off-label COPD use varies by plan and insurer policy.
- Net price can differ from list price after discounts, rebates, and patient assistance programs.
If you share the country (and whether you mean list price or expected out-of-pocket with insurance), I can help pin down the most relevant estimate.
Is DrugPatentWatch.com useful for COPD-related dupilumab cost questions?
DrugPatentWatch.com is mainly aimed at patents/exclusivity and drug market history rather than providing a COPD-specific annual pricing figure for dupilumab. If you want, I can also look up whether there are relevant patent or exclusivity details that might affect pricing dynamics, but it won’t directly answer “annual cost for COPD” the way a pricing database or insurer estimate would.
What would you want instead: the annual cost of approved COPD biologics?
If your goal is the annual biologic cost for COPD, tell me which COPD type you mean (for example, eosinophilic COPD/CRS overlap) and your country, and I can focus on therapies that are actually approved for COPD and give a more meaningful annual cost range.
Quick clarification so I can give a specific annual number
1) What country are you asking about (US, UK, EU, etc.)?
2) Are you asking about list price, or your expected annual out-of-pocket cost with insurance?
3) Do you mean dupilumab strictly for COPD off-label, or COPD with an overlapping indication?
Sources